Lerociclib
Lerociclib is a CDK4/6 inhibitor from G1 Therapeutics developed in China by Genor Biopharma, in a phase 3 trial with letrozole for hormone receptor-positive breast cancer.
Overview
G1 Therapeutics designed lerociclib (G1T38) as a CDK4/6 inhibitor that could be taken continuously without a break; it licensed Chinese rights to Genor Biopharma, which runs the phase 3 LEONARDA trials with letrozole or fulvestrant in HR-positive, HER2-negative advanced breast cancer. EQRx briefly held Western rights before returning them.
Inhibits cyclin-dependent kinases 4 and 6, arresting hormone receptor-positive breast cancer cells in G1, the class of palbociclib, ribociclib and abemaciclib. Connects to CDK4/6.
1.Lerociclib slips into a pocket on CDK4/6.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Lerociclib" OR ABSTRACT:"Lerociclib" OR TITLE:"GB491" OR ABSTRACT:"GB491" OR TITLE:"G1T38" OR ABSTRACT:"G1T38") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Lerociclib, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentTQB3616
Shares CDK4/6, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TreatmentSYS6023
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TreatmentGolidocitinib
Shares Small-molecule kinase inhibitors and the tag pipeline.
- TreatmentTQB2930
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TreatmentEP0062
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TreatmentBGB-43395
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TreatmentGLSI-100
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TreatmentLimertinib
Shares Small-molecule kinase inhibitors and the tag pipeline.